Table 3 PI-MBS and PGIC ratings at Week 12 in eptinezumab-treated ≥ 75% and ≥ 50–< 75% migraine responders (PROMISE-2; eptinezumab pooled)
PI-MBS | PGIC | |||
|---|---|---|---|---|
≥ 50–< 75% | ≥ 75% | ≥ 50–< 75% | ≥ 75% | |
n | 200 | 208 | 200 | 207 |
Very much improved | 33 (16.5%) | 87 (41.8%) | 40 (20.0%) | 75 (36.2%) |
Much improved | 101 (50.5%) | 90 (43.3%) | 99 (49.5%) | 103 (49.8%) |
Minimally improved | 46 (23.0%) | 21 (10.1%) | 40 (20.0%) | 16 (7.7%) |
No change | 14 (7.0%) | 5 (2.4%) | 17 (8.5%) | 10 (4.8%) |
Minimally worse | 5 (2.5%) | 5 (2.4%) | 2 (1.0%) | 3 (1.4%) |
Much worse | 1 (0.5%) | 0 | 2 (1.0%) | 0 |